Invesco Nasdaq Biotechnology ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Virax Biolabs

Rubico

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

STRO

Duality Biotherapeutics has announced a share buyback plan of up to USD 40 million, funded from internal resources, with shares to be held as treasury stock. Chairman and CEO Zhu Zhongyuan will also purchase up to USD 5 million in shares using personal funds. The announcement was made on May 19, 2026.

PUBT

Sutro Biopharma

DUALITYBIO-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Duality Biotherapeutics plans share buyback of up to US$40 million

ABBV

AbbVie and CVS Health appear expensive with trailing P/E multiples over 40, but non-recurring expenses inflate these figures. AbbVie’s forward P/E is 15, while CVS Health’s is 13, indicating they may be undervalued. AbbVie faced a significant drop in net income due to a $2.7 billion charge, while CVS reported a $4 billion loss from goodwill impairment. Both companies show potential for better performance, making them attractive investment options despite their current valuations.

nasdaq

CVS Health

Abbvie

NVIDIA

Intel

S&P 500

NVIDIA Corporation

2 Stocks That Are Much Cheaper Than They Look

HCWB

HCW Biologics Inc. (NASDAQ: HCWB) stock fell 17.16% to $1.12 on Tuesday as investors locked in profits after a 262% surge following strong Q1 earnings. The company reported earnings per share of 37 cents and quarterly sales of $6.54 million. Despite the decline, the stock remains significantly higher overall, driven by advancements in its autoimmune pipeline. Broader market sentiment also contributed to the decline, with Nasdaq futures down 0.75%. Key resistance is at $2.16, while support is at $1.01.

benzinga_article

HCW Biologics

NASDAQ-100

NASDAQ Composite Index

Invesco QQQ Trust

SPDR S&P 500

Nano Labs

Why HCW Biologics Stock Is Falling On Tuesday?

DYAI

Dyadic International will present at Sidoti’s Virtual Investor Conference on May 20, 2026, at 10:00 a.m. ET, and will hold virtual one-on-one investor meetings during the conference window from May 20-21, 2026.

Dyadic

Dyadic COO Hazelton presents at Sidoti Virtual Investor Conference

GOVX

GeoVax Labs (NASDAQ:GOVX) stock is down 13.57% in premarket trading after an 80% rally, following the announcement of a $3M private placement, raising concerns over shareholder dilution. The offering includes approximately 2.03 million shares and warrants for an additional 4.05 million shares. Despite the drop, the stock remains above its 20-day and 50-day SMAs, but is significantly below its 100-day and 200-day SMAs, indicating a long-term downtrend.

GeoVax Labs

Direxion S&P Biotech Bear 3X

Shutterstock

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

Why Is GeoVax Labs Stock Falling Tuesday?

EDSA

Edesa Biotech will present new clinical data on paridiprubart for acute kidney injury at the 63rd European Renal Association Congress in Glasgow from June 3-6, 2026. The analysis indicates a significant reduction in mortality among patients with acute kidney injury, suggesting a potential targeted therapy. An oral presentation is scheduled for June 5, 2026.

Edesa Biotech

Edesa Biotech presents new paridiprubart acute kidney injury data at ERA Congress

REGN

Yesterday, Regeneron Pharma's stock price plummeted 9.82% to $629.68, with a large bearish candlestick engulfing the gains of the previous days. The 5-day and 10-day moving averages were decisively breached, severely damaging the short-term bullish arrangement. The MACD daily line issued a bearish signal below the zero axis, indicating that selling pressure has shifted from testing to active attack, with the short-term trend rapidly weakening. The trading volume reached $1.87 billion, far exceeding the recent average level, showing clear signs of panic selling, with bears completely in control

Technical Forecast

Regeneron Pharma

Pre-market trend | Regeneron Pharma (REGN) plummeted nearly 10% on May 18, is short interest accelerating?

OGEN

Oragenics has initiated Phase IIa dosing of ONP-002 in Australia, with a cash balance of $6.1M and a Letter of Intent for a CNS device. The trial involves 40 patients and focuses on safety and feasibility, with no serious adverse events reported. The company plans to request an FDA Type C meeting in Q2 2026 and aims for a full IND submission by the end of 2026. R&D expenses have increased by 89% to $0.6M, and an annual meeting is scheduled for June 29, 2026.

TradingView

Oragenics

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

PHAR

Pharming has published a corporate presentation reaffirming its full-year revenue guidance of USD 405 million to USD 425 million, projecting 8% to 13% growth. Operating expenses are expected to be between USD 330 million and USD 335 million. First-quarter revenue fell 8%, with RUCONEST revenue down 15%, while Joenja revenue rose 34%. The company highlighted pipeline milestones for Joenja and leniolisib, with key readouts expected in H2 2026.

Pharming Group NV

Pharming publishes corporate presentation outlining rare disease portfolio, 2026 outlook

ALNY

Alnylam Pharmaceuticals has published its 2025 Corporate Responsibility Report, detailing a GHG emissions reduction framework through 2030, supported by third-party review. The report highlights patient access initiatives, including a new Patient Advisory Council and expanded Case Management and Access & Reimbursement teams. Additionally, it discloses a USD 2 million commitment to support Care Navigators in underserved Boston communities through partnerships with local health institutions.

Alnylam Pharma

Direxion Daily Biotech Top 5 Bull 2X ETF

Alnylam publishes 2025 corporate responsibility report

Invesco Nasdaq Biotechnology ETF(IBBQ.US)